Redmile Group, LLC Buys AveXis Inc, Xencor Inc, Atara Biotherapeutics Inc, Sells Clovis Oncology Inc, AstraZeneca PLC, Celgene Corp

• New Purchases: AVXS, SYNH, ALXN, MYL, ARMO, BGNE, ARAY, FLXN, IHF, EXAS,
• Added Positions: XNCR, ATRA, WCG, ANAB, RGNX, ICUI, SYRS, CBAY, PBYI, ABT,
• Reduced Positions: ARRY, UHS, IMGN, LIVN, PEN, MODN, IRTC, EHTH, INSM, MDRX,
• Sold Out: CLVS, AZN, CELG, SGEN, CTLT, TRXC, GMED, PRQR, CASC, PCRX,

For the details of Redmile Group, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Redmile+Group%2C+LLC

1. Array BioPharma Inc (ARRY) - 17,224,428 shares, 11.06% of the total portfolio. Shares reduced by 9.89%
2. Atara Biotherapeutics Inc (ATRA) - 4,236,017 shares, 6.5% of the total portfolio. Shares added by 50.43%
3. Amicus Therapeutics Inc (FOLD) - 10,738,658 shares, 6.36% of the total portfolio. Shares added by 7.11%
4. Immunogen Inc (IMGN) - 9,702,482 shares, 4.02% of the total portfolio. Shares reduced by 11.04%
5. Xencor Inc (XNCR) - 3,204,343 shares, 3.78% of the total portfolio. Shares added by 137.20%

Redmile Group, LLC initiated holding in AveXis Inc. The purchase prices were between $102.08 and $136.93, with an estimated average price of $118.65. The stock is now traded at around $217.83. The impact to a portfolio due to this purchase was 3.1%. The holding were 636,900 shares as of 2018-03-31.

Redmile Group, LLC initiated holding in Syneos Health Inc. The purchase prices were between $31.7 and $44.1, with an estimated average price of $39.25. The stock is now traded at around $46.60. The impact to a portfolio due to this purchase was 2.13%. The holding were 1,526,104 shares as of 2018-03-31.

Redmile Group, LLC initiated holding in Alexion Pharmaceuticals Inc. The purchase prices were between $108.33 and $128.09, with an estimated average price of $119.53. The stock is now traded at around $121.84. The impact to a portfolio due to this purchase was 1.78%. The holding were 404,800 shares as of 2018-03-31.

Redmile Group, LLC initiated holding in Mylan NV. The purchase prices were between $38.87 and $47.64, with an estimated average price of $42.63. The stock is now traded at around $37.45. The impact to a portfolio due to this purchase was 0.62%. The holding were 381,000 shares as of 2018-03-31.

Redmile Group, LLC initiated holding in ARMO BioSciences Inc. The purchase prices were between $29.74 and $54.34, with an estimated average price of $42.29. The stock is now traded at around $49.98. The impact to a portfolio due to this purchase was 0.44%. The holding were 298,800 shares as of 2018-03-31.

Redmile Group, LLC initiated holding in BeiGene Ltd. The purchase prices were between $97.41 and $177.22, with an estimated average price of $134.36. The stock is now traded at around $152.50. The impact to a portfolio due to this purchase was 0.26%. The holding were 40,000 shares as of 2018-03-31.

Redmile Group, LLC added to a holding in Xencor Inc by 137.20%. The purchase prices were between $21.18 and $33.78, with an estimated average price of $26.15. The stock is now traded at around $37.60. The impact to a portfolio due to this purchase was 2.19%. The holding were 3,204,343 shares as of 2018-03-31.

Redmile Group, LLC added to a holding in Atara Biotherapeutics Inc by 50.43%. The purchase prices were between $18 and $48.35, with an estimated average price of $36.18. The stock is now traded at around $36.75. The impact to a portfolio due to this purchase was 2.18%. The holding were 4,236,017 shares as of 2018-03-31.

Redmile Group, LLC added to a holding in WellCare Health Plans Inc by 137.14%. The purchase prices were between $188.41 and $218.79, with an estimated average price of $200.25. The stock is now traded at around $242.19. The impact to a portfolio due to this purchase was 1.51%. The holding were 342,309 shares as of 2018-03-31.

Redmile Group, LLC added to a holding in AnaptysBio Inc by 127.60%. The purchase prices were between $100.5 and $128.55, with an estimated average price of $112.73. The stock is now traded at around $70.01. The impact to a portfolio due to this purchase was 1.2%. The holding were 523,150 shares as of 2018-03-31.

Redmile Group, LLC added to a holding in Regenxbio Inc by 49.51%. The purchase prices were between $24.05 and $37.5, with an estimated average price of $29.15. The stock is now traded at around $73.75. The impact to a portfolio due to this purchase was 0.83%. The holding were 2,130,972 shares as of 2018-03-31.

Redmile Group, LLC added to a holding in ICU Medical Inc by 38.22%. The purchase prices were between $213.2 and $261.85, with an estimated average price of $235.01. The stock is now traded at around $288.60. The impact to a portfolio due to this purchase was 0.53%. The holding were 193,472 shares as of 2018-03-31.

Redmile Group, LLC sold out a holding in Clovis Oncology Inc. The sale prices were between $50.12 and $67.72, with an estimated average price of $58.35.

Redmile Group, LLC sold out a holding in AstraZeneca PLC. The sale prices were between $32.97 and $36.63, with an estimated average price of $34.63.

Redmile Group, LLC sold out a holding in Celgene Corp. The sale prices were between $84.98 and $109.14, with an estimated average price of $96.

Redmile Group, LLC sold out a holding in Seattle Genetics Inc. The sale prices were between $50.14 and $59.32, with an estimated average price of $54.49.

Redmile Group, LLC sold out a holding in Catalent Inc. The sale prices were between $39.4 and $47.39, with an estimated average price of $42.54.

Redmile Group, LLC sold out a holding in TransEnterix Inc. The sale prices were between $1.33 and $2.16, with an estimated average price of $1.76.

Redmile Group, LLC reduced to a holding in Universal Health Services Inc by 68.91%. The sale prices were between $110.15 and $127.27, with an estimated average price of $118.76. The stock is now traded at around $113.50. The impact to a portfolio due to this sale was -0.74%. Redmile Group, LLC still held 67,500 shares as of 2018-03-31.

Redmile Group, LLC reduced to a holding in Model N Inc by 38.63%. The sale prices were between $13.75 and $18.8, with an estimated average price of $16.67. The stock is now traded at around $17.15. The impact to a portfolio due to this sale was -0.22%. Redmile Group, LLC still held 523,937 shares as of 2018-03-31.

Redmile Group, LLC reduced to a holding in CytomX Therapeutics Inc by 20.06%. The sale prices were between $21.11 and $34.22, with an estimated average price of $28.36. The stock is now traded at around $23.02. The impact to a portfolio due to this sale was -0.08%. Redmile Group, LLC still held 334,680 shares as of 2018-03-31.

Redmile Group, LLC reduced to a holding in Ovid Therapeutics Inc by 48.62%. The sale prices were between $6.53 and $9.87, with an estimated average price of $8.12. The stock is now traded at around $8.00. The impact to a portfolio due to this sale was -0.06%. Redmile Group, LLC still held 160,718 shares as of 2018-03-31.